Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17364275 | 0.81 | ALOX15 (0.50) | ADORA3ADORA2AADORA1ALDH1A1GAA | |
| SCHEMBL17364287 | 0.81 | PDPK1 (0.40) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL17364279 | 0.78 | XDH (0.46) | ADORA3ADORA1XDHKDM4EALDH1A1 | |
| SCHEMBL17364327 | 0.75 | XDH (0.44) | ADORA3ADORA2AADORA1XDHALDH1A1 | |
| SCHEMBL3771500 | 0.71 | ADORA3 (0.46) | ADORA3ADORA2AADORA1PIK3CDPIK3R1 | |
| SCHEMBL17860812 | 0.69 | MAPT (0.54) | ADORA3ADORA2AADORA1ADORA2BHTT | |
| SCHEMBL17364273 | 0.68 | PDPK1 (0.43) | KDM4EALDH1A1GAAHPGDTSHR | |
| SCHEMBL17364320 | 0.68 | YTHDC1 (0.41) | ADORA2AADORA1ADORA2BALDH1A1TSHR | |
| SCHEMBL3799224 | 0.67 | XDH (0.44) | ADORA3ADORA2AADORA1XDHKDM4E | |
| SCHEMBL4905421 | 0.64 | ADORA3 (0.65) | ADORA3ADORA2AADORA1XDHADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | ZHONG MINGHONG (US) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376219-A1 | Selective Preparations of Purine Nucleosides and Nucleotides: Reagents and Methods | PNP, ATIC, NT5C3B | ADORA3 66/4885ADORA2A 36/4885ADORA1 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.